السلام عليكم ومبروك عليكم رمضان الكريم.
السهم عليه أخبار ويستحق المتابعة ..تحرك الاسبوع الماضي وعاد اليوم الى نفس الشئ..
بالتوفيق ..
Genasense(R) Clinical Data in Patients with Advanced Melanoma and Chronic Lymphocytic Leukemia to be Presented at ECCO Meeting in Barcelona
BERKELEY HEIGHTS, N.J., Sept 13, 2007 /PRNewswire-FirstCall via COMTEX/ -- Genta Incorporated (Nasdaq: GNTA) announced that new clinical data from the Company's programs for Genasense(R) (oblimersen) in melanoma and chronic lymphocytic leukemia (CLL) will be featured in presentations at the 14th European Cancer Conference, ECCO 14. The conference, sponsored by the Federation of European Cancer Societies (FECS), will take place in Barcelona, Spain from September 23-26, 2007.
FECS represents more than 40,000 experts involved in cancer research, treatment, and care. Under the banner "Cancer in Europe: Sharing the Responsibilities", ECCO 14 provides the largest ever multidisciplinary forum for discussing the entire spectrum of cancer research and management, with an emphasis on translating science into better clinical practice. ECCO 14 is overseen by Dr. John F. Smyth, President of FECS, and Chair of Medical Oncology, University of Edinburgh Medical School; Dr. Jose Baselga, Vice President of FECS, and Chairman and Professor of Medicine, Vall d'Hebron University Hospital, Barcelona; and Dr. Alexander Eggermont, Chair of the ECCO 14 Scientific Committee, President of the European Organization on Research and Treatment of Cancer (EORTC), and Professor of Medicine at the Daniel den Hoed Cancer Center, Erasmus University, Rotterdam.
Titles, dates, and times of the Genasense presentations are as follows:
A Phase 1-2 study to determine the feasibility and efficacy of the triple combination of oblimersen, Abraxane(R), and temozolomide (Temodar(R)) in metastatic melanoma. Oral session: Sept. 26; 09:00-10:45.
Oblimersen plus fludarabine/cyclophosphamide significantly increases complete remission and overall survival in non-refractory patients with relapsed chronic lymphocytic leukemia (CLL): results from a prospective randomized Phase 3 trial. Oral session: Sept 26; 09:00-11:00.
Paired intra-patient pharmacokinetic study of oblimersen in combination with dacarbazine in metastatic melanoma. Poster session: Sept. 25; 14:00- 17:00.
About Genasense in Advanced Melanoma and Chronic Lymphocytic Leukemia
Genasense, Genta's lead anticancer drug, is a novel targeted therapy that blocks the production of Bcl-2, a protein that appears to be a fundamental cause of cancer treatment resistance. By knocking down Bcl-2, Genasense may enhance the effectiveness of chemotherapy in patients with advanced melanoma and CLL.
|
 |
 |
|||
 |
 |
||||
رد مع اقتباس
المشاركة الأصلية كتبت بواسطة DayTradingOnly
المفضلات